MARC details
000 -LEADER |
fixed length control field |
04716nam a22008657a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
160603s20162016 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
0804-4643 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
26671977 |
245 ## - TITLE STATEMENT |
Title |
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer. |
251 ## - Source |
Source |
European Journal of Endocrinology. 174(3):373-80, 2016 Mar. |
252 ## - Abbreviated Source |
Abbreviated source |
EUR. J. ENDOCRINOL.. 174(3):373-80, 2016 Mar. |
253 ## - Journal Name |
Journal name |
European journal of endocrinology / European Federation of Endocrine Societies |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2016 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2016 |
266 ## - Date added to catalog |
Date added to catalog |
2016-06-03 |
520 ## - SUMMARY, ETC. |
Abstract |
CONCLUSIONS: These data demonstrate that sunitinib exhibits significant anti-tumor activity in patients with advanced DTC. Since sunitinib was relatively well-tolerated, there is the potential for clinical benefit in these patients, and further investigation of this agent is warranted.Copyright © 2016 European Society of Endocrinology. |
520 ## - SUMMARY, ETC. |
Abstract |
DESIGN AND METHODS: This was a single center, nonrandomized, open-label, phase 2 clinical trial. In total, 23 patients were enrolled and were treated with a starting daily, oral dose of 37.5 mg sunitinib. Patients were evaluated with imaging, laboratory tests, and physical examination periodically per protocol. |
520 ## - SUMMARY, ETC. |
Abstract |
OBJECTIVE: Our objective was to evaluate the efficacy and safety of sunitinib following at least one course of radioactive iodine treatment in patients with advanced differentiated thyroid cancer (DTC). The study endpoints included best response rate (including best objective response rate) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, measurement of serum thyroglobulin (Tg), and toxicity evaluation. |
520 ## - SUMMARY, ETC. |
Abstract |
RESULTS: The mean best response was a decrease of 17.2% (S.D. 22.8) in tumor sum from baseline. Six (26%) patients achieved a partial response (PR), and 13 (57%) had stable disease (SD) for a clinical benefit rate (PR+SD) of 83%. The overall median PFS was 241 days (interquartile limits, 114-518). No statistically significant difference was observed between the medians of the baseline and post-treatment Tg values (P=0.24). The most common adverse events included grades 1 and 2 decreases in blood cell counts (especially leukocytes), diarrhea, fatigue, hand-foot skin reaction, nausea, musculoskeletal pain, and hypertension. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Adenocarcinoma, Follicular/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Antineoplastic Agents/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Bone Neoplasms/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Carcinoma/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Indoles/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Iodine Radioisotopes/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Lung Neoplasms/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Pyrroles/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Radiotherapy |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Thyroid Neoplasms/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Adenocarcinoma, Follicular/pa [Pathology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Adult |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Aged |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Aged, 80 and over |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Bone Neoplasms/sc [Secondary] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Carcinoma/pa [Pathology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Chemotherapy, Adjuvant |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Diarrhea/ci [Chemically Induced] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Disease-Free Survival |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Fatigue/ci [Chemically Induced] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Female |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Hand-Foot Syndrome/et [Etiology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Leukopenia/ci [Chemically Induced] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Lung Neoplasms/sc [Secondary] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Male |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Middle Aged |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Nausea/ci [Chemically Induced] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Thyroid Neoplasms/pa [Pathology] |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Health Research Institute |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Heart & Vascular Institute |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Endocrinology |
656 ## - INDEX TERM--OCCUPATION |
Department |
Radiology |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Clinical Trial, Phase II |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Research Support, Non-U.S. Gov't |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Barett, Christina |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Bikas, Athanasios |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Burman, Kenneth D |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Clark, Brandon G |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Desale, Sameer |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Gandhi, Rahul |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Jelinek, James S |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Kundra, Priya |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Mete, Mihriye |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
O'Keefe, Kaitlyn |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Wartofsky, Leonard |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Wexler, Jason |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Wray, Lynette |
790 ## - Authors |
All authors |
Barett C, Bikas A, Burman KD, Clark BG, Desale S, Gandhi R, Jelinek JS, Kundra P, Mete M, O'Keefe K, Wartofsky L, Wexler JA, Wray L |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="http://dx.doi.org/10.1530/EJE-15-0930">http://dx.doi.org/10.1530/EJE-15-0930</a> |
Public note |
http://dx.doi.org/10.1530/EJE-15-0930 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |